|Change in clinical status before and after switching|
|Before switching||After switching|
|OLZ-RIS (n=162)||RIS-OLZ (n=136)||OLZ-RIS (n=162)||RIS-OLZ (n=136)|
|Change in CGI-overall score from baselinea(Mean ± SD)||−0.75±1.05||−0.71±1.20||−1.15±1.12||−1.46±1.29|
|Loss of libidob(%)||28.8||37.8||31.3||26.7|
|Change in weight (kg) from baselinec(Mean ± SD)||3.14±6.05||1.43±4.21||4.11±8.39||1.95±8.90|
aThe difference between before and after switching was significant in both groups (p<0.05).
bThe difference between before and after switching was significant only in patients who switched to olanzapine (i.e., the RIS-OLZ group).
cThe difference between before and after switching was not significant in either group.
OLZ-RIS: Patients who switched from olanzapine to risperidone.
RIS-OLZ: Patients who switched from risperidone to olanzapine.
EPS: Extrapyramidal Symptom.
Hong et al.
Hong et al. BMC Psychiatry 2012 12:218 doi:10.1186/1471-244X-12-218